Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Status:
Not yet recruiting
Trial end date:
2024-12-10
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the
safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701
as monotherapy or in combination with either osimertinib or platinum-based chemotherapy in
patients with EGFRm NSCLC.